Study of Aprepitant / Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in Colorectal Cancer Patients - SENRI Trial

NCT01344304 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

413

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer

Interventions

DRUG: Aprepitant / Fosaprepitant

Sponsor

Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group